vs

Side-by-side financial comparison of CANTALOUPE, INC. (CTLP) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

CANTALOUPE, INC. is the larger business by last-quarter revenue ($78.7M vs $74.7M, roughly 1.1× Health Catalyst, Inc.). CANTALOUPE, INC. runs the higher net margin — -0.1% vs -121.9%, a 121.8% gap on every dollar of revenue. On growth, CANTALOUPE, INC. posted the faster year-over-year revenue change (6.8% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-614.0K). Over the past eight quarters, CANTALOUPE, INC.'s revenue compounded faster (7.7% CAGR vs -0.0%).

Cantaloupe, Inc., previously known as USA Technologies Inc., is an American company known for its work with ePort cashless acceptance technology running on its patented ePort Connect service, a PCI compliant services. ePort Connect wirelessly facilitates electronic payment options to consumers with credit, debit, or NFC enabled electronic wallets like Apple Pay and Google Pay while providing operators with both telemetry and machine-to-machine (M2M) services. ePort technology is primarily fou...

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CTLP vs HCAT — Head-to-Head

Bigger by revenue
CTLP
CTLP
1.1× larger
CTLP
$78.7M
$74.7M
HCAT
Growing faster (revenue YoY)
CTLP
CTLP
+13.0% gap
CTLP
6.8%
-6.2%
HCAT
Higher net margin
CTLP
CTLP
121.8% more per $
CTLP
-0.1%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$10.3M more FCF
HCAT
$9.6M
$-614.0K
CTLP
Faster 2-yr revenue CAGR
CTLP
CTLP
Annualised
CTLP
7.7%
-0.0%
HCAT

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
CTLP
CTLP
HCAT
HCAT
Revenue
$78.7M
$74.7M
Net Profit
$-70.0K
$-91.0M
Gross Margin
Operating Margin
2.0%
-115.3%
Net Margin
-0.1%
-121.9%
Revenue YoY
6.8%
-6.2%
Net Profit YoY
-101.4%
-340.3%
EPS (diluted)
$0.00
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTLP
CTLP
HCAT
HCAT
Q4 25
$78.7M
$74.7M
Q3 25
$80.9M
$76.3M
Q2 25
$82.6M
$80.7M
Q1 25
$75.4M
$79.4M
Q4 24
$73.7M
$79.6M
Q3 24
$70.8M
$76.4M
Q2 24
$72.7M
$75.9M
Q1 24
$67.9M
$74.7M
Net Profit
CTLP
CTLP
HCAT
HCAT
Q4 25
$-70.0K
$-91.0M
Q3 25
$-919.0K
$-22.2M
Q2 25
$6.8M
$-41.0M
Q1 25
$49.2M
$-23.7M
Q4 24
$5.0M
$-20.7M
Q3 24
$3.6M
$-14.7M
Q2 24
$2.2M
$-13.5M
Q1 24
$4.7M
$-20.6M
Gross Margin
CTLP
CTLP
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
39.6%
Operating Margin
CTLP
CTLP
HCAT
HCAT
Q4 25
2.0%
-115.3%
Q3 25
2.0%
-22.9%
Q2 25
6.3%
-46.0%
Q1 25
9.1%
-25.4%
Q4 24
8.4%
-22.0%
Q3 24
5.8%
-17.9%
Q2 24
4.9%
-20.8%
Q1 24
6.3%
-30.5%
Net Margin
CTLP
CTLP
HCAT
HCAT
Q4 25
-0.1%
-121.9%
Q3 25
-1.1%
-29.1%
Q2 25
8.3%
-50.8%
Q1 25
65.2%
-29.9%
Q4 24
6.7%
-26.0%
Q3 24
5.0%
-19.3%
Q2 24
3.0%
-17.8%
Q1 24
6.9%
-27.6%
EPS (diluted)
CTLP
CTLP
HCAT
HCAT
Q4 25
$0.00
$-1.29
Q3 25
$-0.02
$-0.32
Q2 25
$0.10
$-0.59
Q1 25
$0.65
$-0.35
Q4 24
$0.07
$-0.33
Q3 24
$0.04
$-0.24
Q2 24
$0.03
$-0.23
Q1 24
$0.06
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTLP
CTLP
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$53.0M
$95.7M
Total DebtLower is stronger
$37.7M
$153.3M
Stockholders' EquityBook value
$252.5M
$245.8M
Total Assets
$381.9M
$502.6M
Debt / EquityLower = less leverage
0.15×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTLP
CTLP
HCAT
HCAT
Q4 25
$53.0M
$95.7M
Q3 25
$55.0M
$91.5M
Q2 25
$51.1M
$97.3M
Q1 25
$46.3M
$342.0M
Q4 24
$27.7M
$392.0M
Q3 24
$33.1M
$387.3M
Q2 24
$58.9M
$308.3M
Q1 24
$50.2M
$327.8M
Total Debt
CTLP
CTLP
HCAT
HCAT
Q4 25
$37.7M
$153.3M
Q3 25
$38.3M
$153.1M
Q2 25
$38.7M
$153.0M
Q1 25
$39.2M
$382.9M
Q4 24
$37.0M
$382.4M
Q3 24
$37.3M
$345.0M
Q2 24
$37.5M
Q1 24
$38.1M
Stockholders' Equity
CTLP
CTLP
HCAT
HCAT
Q4 25
$252.5M
$245.8M
Q3 25
$251.8M
$331.9M
Q2 25
$251.0M
$347.5M
Q1 25
$240.7M
$376.8M
Q4 24
$190.1M
$365.2M
Q3 24
$186.2M
$355.0M
Q2 24
$181.7M
$357.0M
Q1 24
$178.8M
$357.2M
Total Assets
CTLP
CTLP
HCAT
HCAT
Q4 25
$381.9M
$502.6M
Q3 25
$389.5M
$587.1M
Q2 25
$381.9M
$616.2M
Q1 25
$370.5M
$891.5M
Q4 24
$303.0M
$858.9M
Q3 24
$312.1M
$813.0M
Q2 24
$335.6M
$691.7M
Q1 24
$319.9M
$695.1M
Debt / Equity
CTLP
CTLP
HCAT
HCAT
Q4 25
0.15×
0.62×
Q3 25
0.15×
0.46×
Q2 25
0.15×
0.44×
Q1 25
0.16×
1.02×
Q4 24
0.19×
1.05×
Q3 24
0.20×
0.97×
Q2 24
0.21×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTLP
CTLP
HCAT
HCAT
Operating Cash FlowLast quarter
$3.1M
$9.9M
Free Cash FlowOCF − Capex
$-614.0K
$9.6M
FCF MarginFCF / Revenue
-0.8%
12.9%
Capex IntensityCapex / Revenue
4.8%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$25.8M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTLP
CTLP
HCAT
HCAT
Q4 25
$3.1M
$9.9M
Q3 25
$7.0M
$-464.0K
Q2 25
$9.4M
$-9.0M
Q1 25
$22.4M
$280.0K
Q4 24
$522.0K
$-3.5M
Q3 24
$-12.0M
$6.2M
Q2 24
$14.3M
$1.6M
Q1 24
$14.7M
$10.3M
Free Cash Flow
CTLP
CTLP
HCAT
HCAT
Q4 25
$-614.0K
$9.6M
Q3 25
$3.5M
$-719.0K
Q2 25
$4.3M
$-9.2M
Q1 25
$18.6M
$-390.0K
Q4 24
$-3.8M
$-3.9M
Q3 24
$-15.8M
$5.5M
Q2 24
$8.5M
$1.3M
Q1 24
$11.4M
$10.1M
FCF Margin
CTLP
CTLP
HCAT
HCAT
Q4 25
-0.8%
12.9%
Q3 25
4.4%
-0.9%
Q2 25
5.3%
-11.4%
Q1 25
24.6%
-0.5%
Q4 24
-5.1%
-4.9%
Q3 24
-22.3%
7.2%
Q2 24
11.7%
1.7%
Q1 24
16.9%
13.5%
Capex Intensity
CTLP
CTLP
HCAT
HCAT
Q4 25
4.8%
0.4%
Q3 25
4.2%
0.3%
Q2 25
6.2%
0.3%
Q1 25
5.1%
0.8%
Q4 24
5.8%
0.5%
Q3 24
5.4%
0.9%
Q2 24
7.9%
0.4%
Q1 24
4.8%
0.3%
Cash Conversion
CTLP
CTLP
HCAT
HCAT
Q4 25
Q3 25
Q2 25
1.38×
Q1 25
0.46×
Q4 24
0.10×
Q3 24
-3.36×
Q2 24
6.47×
Q1 24
3.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTLP
CTLP

Transaction Processing$47.9M61%
Subscription Revenue$21.8M28%
Products$9.0M11%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons